News & Articles

New service addresses the urgent need for ultra-fast, high-quality genes

cPass is first commercially available product to rapidly detect neutralizing antibodies capable of eliminating virus

Read this application note to discover how T cell activation assays can help accelerate COVID-19 vaccine development

The cPass™ – SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit aims to detect the presence of neutralizing antibodies in an hour

Services expedite downstream screening time with precision control and complete variant coverage

MonoRab™; superior antibody generation with a stress-free workflow that ensures delivery of the most clones for application-based testing, 10 different mAb variable chain sequences, and expert level recombinant antibody expression

Advanced semiconductor-based platform offers diverse libraries with complete coverage of only desired variants

Proprietary enzymatic synthesis technology produces high-quality sequences up to 3,000 nucleotides long